4 Imperatives For Updating Our Clinical Quality Systems Approach For 2022 Pharma

July 29, 2021
By Penelope Przekop
Clinical
Quality Systems
Quality Assurance
Risk Management

The clinical quality management systems approach developed 20 years ago is not sustainable in the today's industry because we've seen dramatic industry changes in outsourcing, remote monitoring, the use of electronic systems in clinical research, and more. But how do we update our approach for 2022 pharma? This article examines 4 imperatives, including how to accomplish them.

About the Author

Penelope Przekop, CEO

MSQA, RQAP-GCP

Penelope Przekop is a is a biopharmaceutical quality assurance and corporate compliance executive consultant with global R&D and commercial PV expertise. During the early 2000s, she developed and oversaw the first global PV quality and compliance departments established for Wyeth as well as Johson & Johnson. Her work includes qualification and oversight of numerous PV vendors covering all aspects of clinical safety and post-marketed PV. Penelope has facilitated numerous PV regulatory inspections. She frequently leads and conducts PV mock inspections and provides in-depth PV training.

Related Content

Read more from PDC’s teams of experts.

A 3-Point Strategy For Training Part-Time GCP Consultants

Global biopharma regulations and guidelines require that individuals involved in conducting clinical trials be qualified by a combination of education, training, and experience. The components are straightforward to implement regarding internal employees, but not so clear when it comes to part-time consultants contracted to intermittently execute specific good clinical practice (GCP) tasks. Discover three trips for training independent consultants.

Learn more
A 3-Point Strategy For Training Part-Time GCP Consultants

Global biopharma regulations and guidelines require that individuals involved in conducting clinical trials be qualified by a combination of education, training, and experience. The components are straightforward to implement regarding internal employees, but not so clear when it comes to part-time consultants contracted to intermittently execute specific good clinical practice (GCP) tasks. Discover three trips for training independent consultants.

Learn more
The FDA Speaks Up For Quality Management: Must They Beg?

On Jan. 31, 2024, the FDA, in collaboration with the Duke-Margolis Institute for Health Policy, convened a public workshop, Building Quality into the Design and Conduct of Clinical Studies: Integrating Quality by Design (QbD) and Risk-Based Monitoring (RBM) Approaches.

Learn more
The FDA Speaks Up For Quality Management: Must They Beg?

On Jan. 31, 2024, the FDA, in collaboration with the Duke-Margolis Institute for Health Policy, convened a public workshop, Building Quality into the Design and Conduct of Clinical Studies: Integrating Quality by Design (QbD) and Risk-Based Monitoring (RBM) Approaches.

Learn more
3 Reasons Why Sponsors Must Review Monitoring Reports

Despite recent progress in executing and documenting oversight, sponsor oversight remains a challenge, especially with monitoring reports. Penelope Przekop detail three reasons why they must remain top of mind.

Learn more
3 Reasons Why Sponsors Must Review Monitoring Reports

Despite recent progress in executing and documenting oversight, sponsor oversight remains a challenge, especially with monitoring reports. Penelope Przekop detail three reasons why they must remain top of mind.

Learn more
How Biopharma Leaders Can Ward Off A Perfect Storm: Part 2

Amid all this financial and operational strategizing, a huge puzzle piece is often left to the side: compliance.

Learn more
How Biopharma Leaders Can Ward Off A Perfect Storm: Part 2

Amid all this financial and operational strategizing, a huge puzzle piece is often left to the side: compliance.

Learn more

How can we help you?

Reach out to schedule a consultation.

Contact PDC